Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × Docetaxel × Genitourinary × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 267 Urinary Bladder Neoplasms 39 Neoplasm Metastasis 31 Carcinoma, Transitional Cell 22 Carcinoma, Non-Small-Cell Lung 22 Neoplasms 19 Breast Neoplasms 19 Lung Neoplasms 14 Carcinoma, Renal Cell 12 Squamous Cell Carcinoma of Head and Neck 11 Stomach Neoplasms 10 Ovarian Neoplasms 10 Non-Muscle Invasive Bladder Neoplasms 10 Melanoma 8 Head and Neck Neoplasms 7 Esthesioneuroblastoma, Olfactory 7 Urethral Neoplasms 6 Small Cell Lung Carcinoma 6 Salivary Gland Neoplasms 6 Prostatic Neoplasms, Castration-Resistant 6 Esophageal Neoplasms 6 Triple Negative Breast Neoplasms 5 Prostate Cancer Metastatic 5 Metastatic Castration-resistant Prostate Cancer 5 Kidney Neoplasms 5 Colorectal Neoplasms 5 Uterine Cervical Neoplasms 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Pancreatic Neoplasms 4 Pain 4

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 niraparib 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Radiotherapy 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Everolimus 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03390504 2026-02-02

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡